Department of Health and Human Services logoDepartment of Health and Human Services

Public Health Service
Food and Drug Administration
 College Park, MD 20740 

 

WARNING LETTER
 
September 2, 2016
 
VIA EXPRESS DELIVERY
 
Margaret Hardy, President
Harrington House Ltd.
285 Hawthorne Drive
Danville, VA 24541-3619
 
Re: CMS#501665
 
This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address http://www.abbeystclare.com/ in July 2016 and has determined that you take orders there for the products Abbey St. Clare Botanical Oil #5: Recovery, Abbey St. Clare Lavender High Altitude French Essential Oil, Abbey St. Clare Australian Emu Oil, Abbey St. Clare Kettle Soap – Certified Organic Formulas, Abbey St. Clare Spot Remover & Blemish Control Poultice, and Abbey St. Clare Pomegranate Protection Hydrating Mist. The claims on your website establish that the products are drugs under sections 201(g)(1)(B) and/or 201 (g)(1)(C) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B) and/or 21 U.S.C. § 321(g)(1)(C)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or articles intended to affect the structure or any function of the human body.  As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.  You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov
 
Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:
 
Abbey St. Clare Botanical Oil #5: Recovery
Abbey St. Clare Lavender High Altitude French Essential Oil 
Abbey St. Clare Australian Emu Oil  
Abbey St. Clare Kettle Soap – Certified Organic Formulas 
Abbey St. Clare Spot Remover & Blemish Control Poultice 
Abbey St. Clare Pomegranate Protection Hydrating Mist 
Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective. 
 
This letter is not an all-inclusive statement of violations associated with your products or their labeling, and we have not attempted to list here all of the products that are promoted on your website for intended uses that cause them to be drugs.  It is your responsibility to ensure that all products marketed by your firm comply with the Act and its implementing regulations.  We advise you to review your website, product labels, and other labeling for your products to ensure that the claims you make for your products do not reflect intended uses that cause the distribution of the products to violate the Act.
 
We request that you take prompt action to correct all violations associated with your products, including the violations identified in this letter. Failure to do so may result in enforcement action without further notice. The Act authorizes injunctions against manufacturers and distributors of illegal products and seizure of such products.
 
Please notify this office in writing within fifteen (15) working days of the receipt of this letter as to the specific steps you have taken to correct the stated violations, including an explanation of each step being taken to identify violations and make corrections to ensure that similar violations will not recur. If you do not believe that your products are in violation of the Act, include your reasoning and any supporting information for our consideration. If the corrective action cannot be completed within fifteen working days, state the reason for the delay and the time frame within which the corrections will be implemented.
 
If you need additional information or have questions concerning any products distributed through your website, please contact the FDA. You may respond in writing to Ms. Cherlita Honeycutt, Compliance Officer, U.S. Food and Drug Administration, 6000 Metro Drive, Suite 101, Baltimore, Maryland 21215. If you have any questions about the contents of this letter, please contact Ms. Honeycutt at (410) 779-5412 or via fax at (410) 779-5705.
 
Sincerely,
/S/                                                           
Evelyn Bonnin
District Director

This page was posted on March 28, 2019.

Links to Recommended Companies

  • PharmacyChecker.com: Compare drug prices and save money at verified online pharmacies.
  • ConsumerLab.com: Evaluates the quality of dietary supplement and herbal products.
  • Amazon.com: Discount prices, huge inventory, and superb customer service.
  • OnlyMyEmail: Award-winning anti-spam services.
  • 10 Types: Website design, development, and hosting with superb technical support.